ALKS — Alkermes plc
Is ALKS overbought or oversold? Here is the current MarketMoodz read.
Alkermes plc (ALKS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $45.45. The rating moved from Overbought to Neutral on November 12, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$45.45
- Last changeMoved from Overbought to Neutral on November 12, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
AI analysis
Alkermes is a specialty pharma with commercial products that generate near-term cash flow while its pipeline provides medium-term upside tied to clinical outcomes and partnerships. Market dynamics favor large-cap defensive pharma, so ALKS faces muted sector tailwinds; however, trends toward specialty distribution and sustained demand for injectable specialty therapies are supportive. Key near-term drivers include product-level reimbursement dynamics, upcoming clinical readouts or partner announcements, and any changes to liquidity or capital structure. Downside is driven by reimbursement pressure, clinical setbacks, and competitive displacement; upside depends on successful development milestones or favorable commercial execution.
Key factors
- Diversified product mix with legacy commercial revenue drivers (e.g., specialty CNS and addiction-treatment products) providing near-term cash flow support
- Mid-stage pipeline and development-stage assets that offer upside if clinical readouts are positive or partnered successfully
- Strategic partnerships and manufacturing/service relationships that support specialty distribution and potential revenue stability
- Favorable distributor and specialty pharmacy trends that could sustain prescription flows for injectable/specialty products
- Moderate balance sheet / liquidity profile that appears adequate for near-term operations but could require additional financing or partnering for larger development programs
- Sector-wide defensive flows into large-cap pharma limit near-term momentum for smaller specialty names, creating a mixed market backdrop
Risks
- Revenue concentration risk from a small number of commercial products; loss of market share or payer restrictions would materially impact top-line
- Reimbursement and Medicare/Medicaid program integrity actions could tighten access or increase clawbacks, pressuring net pricing
- Clinical and regulatory risk for pipeline assets; negative trial outcomes would reduce upside and investor confidence
- Competition from established and emerging treatments in addiction and CNS spaces, including long-acting injectables from peers
- Funding risk if clinical programs require additional capital or deal terms that dilute existing shareholders
- General biotech/SMid-cap volatility and limited social sentiment data increase sensitivity to headline-driven moves
See today's live rating, score and targets
Members see the live hourly rating for ALKS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.